Laboratory of Glycoconjugates

The laboratory of glycoconjugates was established in January 2007 as a research-service team within the Technology Transfer Department. Its main program consists in transforming research results achieved in the field of non-pyrogenic immunostimulating glycopeptides to clinical use. The results collected thus far established this novel group of muramyl glycopeptide analogs as remarkably potent immunotherapeutics which can be utilized potentially as structurally well defined and safe adjuvans. These enable construction of a new generation of vaccines (sub-unit, recombinant and gene), as therapeutics able to amplify innate anti-inflammatory and anti-tumor activity or restore haemopoesis damaged by radio- or chemo-therapy.

Within the Institute this program represents a unique pilot project which. besides the above mentioned commercialization, aims at creating a more general technical and methodical platform capable of servicing rather routinely also analogous cases inside IOCB. For this purpose a spin-off company, Mendel Therapeutics l.t.d., was set up.